Fig. 2From: Lower mutant-allele tumor heterogeneity is a biomarker in FGFR3-mutant bladder cancer for better prognosisCharacteristics of the variants in the BLCA study cohort. a Scatter plot comparing the mutational loads of the BLCA cohort with other TCGA cancer cohorts. b Distribution of the mutant-allele tumor heterogeneity (MATH) values among bladder cancer patients. c Q–Q (quantile–quantile) plot analysis of the distribution of all MATH valuesBack to article page